上海市公共卫生临床中心2005～2007年抗HBV核苷类药物的利用分析

Analysis of Anti-HBV nucleoside analogues used in Shanghai Public health clinical center during 2005-2007

目的调研上海市公共卫生临床中心近年来抗HBV核苷类药物的使用情况，为临床合理用药提供依据。方法收集本院2005-2007年抗HBV核苷类药物的使用数据，对其用药金额和用药频度等数据进行统计分析。结果我院抗HBV核苷类药物的用药金额呈逐年上升趋势，2006年与2007年用药金额增长幅度分别为178．00％和68．99％，该类药品年增长的幅度远远超出了总药品金额的增长；在药品构成比中拉米夫定逐年下降，但在用药频度排序中，始终为第一位；各品种日均费用稳中稍降，思替卡韦位列第一。结论我院抗HBV核苷类药物使用正逐步规范合理，但仍应密切注意耐药情况，根据病人具体情况，合理选用药物。

Objective To investigate the utilization of Anti-HBV nucleoside analogues in Shanghai Public health clinical center in recent years and to offer the guideline for doctors in clinical rational use of the drugs. Methods The data of Anti-HBV nucleoside analogues used in this hospital during 2005-2007 were collected. The consumption sum of Anti-HBV nucleoside analogues and frequency of drug usage （DDDs） were analyzed. Results The consumption sum of Anti-HBV nucleoside analogues showed an increasing tendency year by year in this hospital. In 2006 and 2007, the growth rate of consumption sum of the drugs were： 178% and 68.99% respectively, and they were higher than that of all drugs used in this hospital. The composition ratio of Lamivudine decreased year by year, but the DDDs was always the top l; the cost of daily average decreased slightly, Entecavir was the highest. Conclusions The utilization of Anti-HBV nucleoside analogues is gradually rationalized in the Hospital, but it should pay more attention to the drug resistance when choosing a drag according to the patients.